OncoMatch/Clinical Trials/NCT05169970
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
Is NCT05169970 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for prostate cancer.
The researchers are doing this study to find out if stereotactic body radiation therapy (SBRT) without androgen deprivation therapy (ADT) is an effective treatment approach for people with unfavorable intermediate-risk prostate. The researchers will see whether SBRT can prevent participants' cancer from coming back and/or spreading to other parts of the body. In addition, they will look closely at how safe and effective it is to rely on Decipher test results for determining which patients would benefit from more extensive radiation treatments
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage UNFAVORABLE INTERMEDIATE RISK (NCCN 2021), CT2B, CT2C (NCCN 2021)
Grade: Gleason Score 4+3Grade Group 2Grade Group 3 (Gleason / Grade Group)
Unfavorable intermediate risk prostate cancer by NCCN 2021 risk stratification guidelines, including any of the following clinicopathologic features: Gleason Score 4+3; ≥ 50% biopsy cores positive; Two or more of the following risk factors: Grade Group 2 or 3, cT2b-T2c, PSA 10 - 20 ng/mL. Radiographic T3-T4 detected on staging mpMRI [excluded].
Performance status
KPS OR ECOG 0–2
KPS ≥ or ECOG 0-2
Prior therapy
Cannot have received: chemotherapy
Prior treatment for prostate cancer including chemotherapy, surgery, or hormonal therapy
Cannot have received: surgery
Prior treatment for prostate cancer including chemotherapy, surgery, or hormonal therapy
Cannot have received: hormonal therapy
Prior treatment for prostate cancer including chemotherapy, surgery, or hormonal therapy
Cannot have received: radiation therapy
Prior pelvic radiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify